UROFIX
UROKINASE · by ALLMED LABS
Composition
lnj: Per vial: Urokinase 25,000/50,000 units; powder for reconstitution.
Indications & Dosage
Deep-vein thrombosis (thromboembolic occlusive vascular disease): Adult: Initially 4400 units/kg, over 10 minutes, in 15ml sodium chloride 0.9%, followed by 4400 units/kg/hr for 12-24 hrs. Pulmonary embolism (thromboembolic occlusive vascular disease): Adult: Initially 4400 units/kg, over 10 minutes, in 15ml sodium chloride 0.9%, followed by (by IV INF) 4400 mcg/kg/hr for 12 hrs, alternatively (by intra-arterial injection) initially 15000 units/kg, to be injected into pulmonary artery, subsequent doses adjusted according to response; max. 3 doses per day. Occlusive peripheral arterial disease: BY INTRA-ARTERIAL INF: Adult: Consult product literature Occluded intravenous catheters and cannulas (blocked by fibrin clots): BY INTRA-ARTERIAL OR IV INJ: Adult: 5000-25 000 units, to be injected directly into catheter or cannula, dissolved in sodium chloride 0.9% to fill the catheter or cannula lumen; leave for 20-60 min then aspirate the lysate; repeat if necessary.
Administration
Administer using a pump which can deliver a total volume of 195 ml. The loading dose should be administered at 90 ml/hour over 10 min. The maintenance dose is 15 ml/hour over 12 hours.
Compatibility
Stable in NS or DOW.
Contraindications
Recent bleeding following surgery, cerebrovascular bleeding, severe hypertension.
Precautions
Hepatic impairment and renal impairment; dose reduction may be required, Peptic ulcer or risk of GI bleeding, recent repeated intravascular or intra-cardiac puncture, recent cardiopulmonary resuscitation.
Pregnancy
Contraindicated
Lactation
Caution advised
Side Effects
Local irritation, bleeding and haemorrhagic complications, pyrexia, haematuria, embolic episodes, cholesterol embolism, allergic reactions.